DK3235812T3 - Deutererede derivater af ivacaftor - Google Patents

Deutererede derivater af ivacaftor Download PDF

Info

Publication number: DK3235812T3
Authority: DK; Denmark
Prior art keywords: ivacaftor; deuterated derivatives; deuterated; derivatives
Prior art date: 2011-05-18

Application number

DK17160386T

Other languages

English (en)

Inventor

Adam J Morgan

Original Assignee

Vertex Pharmaceuticals Europe Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-05-18

Filing date

2012-05-17

Publication date

2019-11-25

2012-05-17 Application filed by Vertex Pharmaceuticals Europe Ltd filed Critical Vertex Pharmaceuticals Europe Ltd

2019-11-25 Application granted granted Critical

2019-11-25 Publication of DK3235812T3 publication Critical patent/DK3235812T3/da

Links

PURKAOJPTOLRMP-UHFFFAOYSA-N ivacaftor Chemical class C1=C(O)C(C(C)(C)C)=CC(C(C)(C)C)=C1NC(=O)C1=CNC2=CC=CC=C2C1=O PURKAOJPTOLRMP-UHFFFAOYSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Quinoline Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Saccharide Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Thiazole And Isothizaole Compounds (AREA)

DK17160386T 2011-05-18 2012-05-17 Deutererede derivater af ivacaftor DK3235812T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201161487497P	2011-05-18	2011-05-18
EP12725197.3A EP2709986B1 (en)	2011-05-18	2012-05-17	Deuterated derivatives of ivacaftor

Publications (1)

Publication Number	Publication Date
DK3235812T3 true DK3235812T3 (da)	2019-11-25

Family

ID=46201810

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK17160386T DK3235812T3 (da)	2011-05-18	2012-05-17	Deutererede derivater af ivacaftor
DK12725197.3T DK2709986T3 (da)	2011-05-18	2012-05-17	Deutererede derivater af ivacaftor

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK12725197.3T DK2709986T3 (da)	2011-05-18	2012-05-17	Deutererede derivater af ivacaftor

Country Status (20)

Country	Link
EP (2)	EP3235812B1 (da)
JP (2)	JP6063455B2 (da)
AU (5)	AU2012255711B2 (da)
BR (1)	BR112013029240B1 (da)
CA (1)	CA2834574C (da)
CY (2)	CY1119090T1 (da)
DK (2)	DK3235812T3 (da)
EA (1)	EA028378B1 (da)
ES (2)	ES2758028T3 (da)
HR (2)	HRP20170754T1 (da)
HU (1)	HUE032771T2 (da)
LT (1)	LT2709986T (da)
ME (2)	ME03652B (da)
MX (1)	MX349159B (da)
PL (2)	PL2709986T3 (da)
PT (2)	PT3235812T (da)
RS (2)	RS56096B1 (da)
SI (2)	SI2709986T1 (da)
SM (2)	SMT201700302T1 (da)
WO (1)	WO2012158885A1 (da)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK3219705T3 (da)	2005-12-28	2020-04-14	Vertex Pharma	Farmaceutiske sammensætninger af den amorfe form af n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid
US12458635B2 (en)	2008-08-13	2025-11-04	Vertex Pharmaceuticals Incorporated	Pharmaceutical composition and administrations thereof
DK3235812T3 (da) *	2011-05-18	2019-11-25	Vertex Pharmaceuticals Europe Ltd	Deutererede derivater af ivacaftor
HUE047354T2 (hu)	2011-05-18	2020-04-28	Vertex Pharmaceuticals Europe Ltd	Ivacaftor deuterizált származékai
JP2015511583A (ja)	2012-02-27	2015-04-20	バーテックスファーマシューティカルズインコーポレイテッドＶｅｒｔｅｘＰｈａｒｍａｃｅｕｔｉｃａｌｓＩｎｃｏｒｐｏｒａｔｅｄ	薬学的組成物およびその投与
AU2013243857A1 (en) *	2012-04-06	2014-10-16	The Uab Research Foundation	Methods for increasing CFTR activity
JP6146990B2 (ja) *	2012-11-16	2017-06-14	コンサートファーマシューティカルズインコーポレイテッド	重水素化されたｃｆｔｒ増強物質
WO2014078842A1 (en) *	2012-11-19	2014-05-22	Concert Pharmaceuticals, Inc.	Deuterated cftr potentiators
RS60906B1 (sr)	2014-10-06	2020-11-30	Vertex Pharma	Modulatori regulatora transmembranske provodljivosti za cističnu fibrozu
CN107250113B (zh)	2014-10-07	2019-03-29	弗特克斯药品有限公司	囊性纤维化跨膜传导调节蛋白的调节剂的共晶
HK1249893A1 (zh)	2015-03-31	2018-11-16	Vertex Pharmaceuticals (Europe) Limited	氘代vx-661
US10548878B2 (en)	2015-07-24	2020-02-04	Proteostasis Therapeutics, Inc.	Compounds, compositions, and methods of increasing CFTR activity
US20180353500A1 (en) *	2015-09-21	2018-12-13	Vertex Pharmaceuticals (Europe) Limited	Administration of deuterated cftr potentiators
EP3352758A4 (en) *	2015-09-25	2018-08-01	Vertex Pharmaceuticals (Europe) Limited	Deuterated cftr potentiators
US10662207B2 (en) *	2016-04-07	2020-05-26	Proteostasis Therapeutics, Inc.	Compounds, compositions, and methods for modulating CFTR
US10899751B2 (en)	2016-06-21	2021-01-26	Proteostasis Therapeutics, Inc.	Compounds, compositions, and methods for increasing CFTR activity
PT3551622T (pt)	2016-12-09	2020-11-12	Vertex Pharma	Modulador do regulador da condutância transmembrana da fibrose quística, composições farmacêuticas, métodos de tratamento e processo de fabrico do modulador
JP2017105824A (ja) *	2017-02-10	2017-06-15	コンサートファーマシューティカルズインコーポレイテッド	重水素化されたｃｆｔｒ増強物質
WO2019018395A1 (en)	2017-07-17	2019-01-24	Vertex Pharmaceuticals Incorporated	METHODS OF TREATING CYSTIC FIBROSIS
CN117924170A (zh)	2017-12-01	2024-04-26	弗特克斯药品有限公司	用于制备囊性纤维化跨膜传导调节因子的调节剂的方法
CA3085006A1 (en)	2017-12-08	2019-06-13	Vertex Pharmaceuticals Incorporated	Processes for making modulators of cystic fibrosis transmembrane conductance regulator
JP6654223B2 (ja) *	2018-08-13	2020-02-26	バーテックスファーマシューティカルズ（ヨーロッパ）リミテッド	重水素化されたｃｆｔｒ増強物質
TWI848092B (zh)	2019-04-03	2024-07-11	美商維泰克斯製藥公司	囊腫纖維化跨膜傳導調節蛋白調節劑
WO2020214921A1 (en)	2019-04-17	2020-10-22	Vertex Pharmaceuticals Incorporated	Solid forms of modulators of cftr
TWI867024B (zh)	2019-08-14	2024-12-21	美商維泰克斯製藥公司	囊腫纖維化跨膜傳導調節蛋白之調節劑
TWI899097B (zh)	2019-08-14	2025-10-01	美商維泰克斯製藥公司	製備cftr調節劑之方法
US11873300B2 (en)	2019-08-14	2024-01-16	Vertex Pharmaceuticals Incorporated	Crystalline forms of CFTR modulators
IL290408B2 (en)	2019-08-14	2025-10-01	Vertex Pharma	Cystic fibrosis transmembrane conductance regulator modulators
LV15575A (lv)	2019-12-20	2021-06-20	Latvijas Organiskās Sintēzes Institūts	Selenofēnhromēnu deiterēti analogi, to iegūšana un izmantošana
CR20230120A (es)	2020-08-07	2023-09-01	Vertex Pharma	Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
WO2022036060A1 (en)	2020-08-13	2022-02-17	Vertex Pharmaceuticals Incorporated	Crystalline forms of cftr modulators
EP3970718A1 (en)	2020-09-18	2022-03-23	Charité - Universitätsmedizin Berlin	New medical use of cystic fibrosis transmembrane conductance regulator (cftr) modulators
IL301755A (en)	2020-10-07	2023-05-01	Vertex Pharma	Modulators of cystic fibrosis transmembrane conductance regulator
EP4225761A1 (en)	2020-10-07	2023-08-16	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
US20230416275A1 (en)	2020-10-07	2023-12-28	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
US12612416B2 (en)	2020-10-07	2026-04-28	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
CA3197173A1 (en)	2020-10-07	2022-04-14	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
US20230373935A1 (en)	2020-10-07	2023-11-23	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
MX2023004072A (es)	2020-10-07	2023-07-05	Vertex Pharma	Moduladores del regulador de la conductancia transmembrana de la fibrosis quistica.
US20230373974A1 (en)	2020-10-07	2023-11-23	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
EP4225737A1 (en)	2020-10-07	2023-08-16	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
US20230382924A1 (en)	2020-10-07	2023-11-30	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
US12324802B2 (en)	2020-11-18	2025-06-10	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
IL303519A (en)	2020-12-10	2023-08-01	Vertex Pharma	Cystic fibrosis treatment methods
IL314691A (en)	2022-02-03	2024-10-01	Vertex Pharma	PREPARATION METHODS AND CRYSTALLINE FORMS OF (6A,12A)-17-AMINO-12-METHYL-6,15-BIS(TRIFLUOROMETHYL)-13,19-DIOXA-3,4,18-TRIAZATRICYCLO[ 12.3.112.3.1. NONADECA-1(18),2,4,14,16-PENTAEN-6-OL
CA3249378A1 (en)	2022-02-03	2023-08-10	Vertex Pharmaceuticals Incorporated	TREATMENT METHODS FOR CYSTIC FIBROSIS
CN118974059A (zh)	2022-02-08	2024-11-15	弗特克斯药品有限公司	囊性纤维化跨膜传导调控因子的调节剂
CR20240457A (es)	2022-04-06	2024-12-11	Vertex Pharma	Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
CA3253026A1 (en)	2022-05-16	2023-11-23	Vertex Pharmaceuticals Incorporated	TREATMENT METHODS FOR CYSTIC FIBROSIS
WO2023224924A1 (en)	2022-05-16	2023-11-23	Vertex Pharmaceuticals Incorporated	Solid forms of a macrocyclic compounds as cftr modulators and their preparation
WO2025076235A1 (en)	2023-10-04	2025-04-10	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
IL327468A (en)	2023-10-04	2026-05-01	Vertex Pharmaceuticals Incorporated	Solid forms of cystic fibrosis transmembrane conductance regulator
WO2025166342A1 (en)	2024-02-04	2025-08-07	Vertex Pharmaceuticals Incorporated	Combination of vanzacaftor, tezacaftor, deutivacaftor for use in treating cystic fibrosis
DK4648753T3 (da)	2024-02-07	2026-02-23	Vertex Pharma	Sammensætninger til behandling af cftr-medierede sygdomme

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1087725C (zh) *	1994-03-25	2002-07-17	同位素技术有限公司	用氘代方法增强药物效果
GB9925962D0 (en)	1999-11-02	1999-12-29	Novartis Ag	Organic compounds
PT1390063E (pt)	2001-05-03	2005-03-31	Hoffmann La Roche	Forma de dosagem farmaceutica de mesilato de nelfinavir amorfo
JP2005503425A (ja)	2001-05-24	2005-02-03	アレックザモレキュラーデリヴァリーコーポレイション	所定の吸入ルートによる薬剤エステルの送出
CN101891680B (zh)	2004-06-24	2014-10-29	沃泰克斯药物股份有限公司	Atp-结合弹夹转运蛋白的调控剂
US20060094744A1 (en)	2004-09-29	2006-05-04	Maryanoff Cynthia A	Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
AU2006331565A1 (en)	2005-12-27	2007-07-05	Vertex Pharmaceuticals Incorporated	Compounds useful in CFTR assays and methods therewith
DK3219705T3 (da)	2005-12-28	2020-04-14	Vertex Pharma	Farmaceutiske sammensætninger af den amorfe form af n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid
AU2007249269A1 (en)	2006-05-12	2007-11-22	Vertex Pharmaceuticals Incorporated	Compositions of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl)-1,4-dihydro-4-oxoquinoline-3-carboxamide
JP5647519B2 (ja) *	2007-09-13	2014-12-24	コンサートファーマシューティカルズインコーポレイテッド	重水素化カテコールおよびベンゾ［ｄ］［１，３］ジオキソールおよびその誘導体の合成
KR20110042356A (ko)	2008-08-13	2011-04-26	버텍스 파마슈티칼스 인코포레이티드	제약 조성물 및 그의 투여
US20100074949A1 (en)	2008-08-13	2010-03-25	William Rowe	Pharmaceutical composition and administration thereof
MX2011002033A (es) *	2008-09-03	2011-05-02	Teva Pharma	2-oxo-1,2-dihidro-quinolinas moduladoras de la funcion inmune.
DK3235812T3 (da) *	2011-05-18	2019-11-25	Vertex Pharmaceuticals Europe Ltd	Deutererede derivater af ivacaftor

2012
- 2012-05-17 DK DK17160386T patent/DK3235812T3/da active
- 2012-05-17 SI SI201230988A patent/SI2709986T1/sl unknown
- 2012-05-17 ME MEP-2019-325A patent/ME03652B/me unknown
- 2012-05-17 SM SM20170302T patent/SMT201700302T1/it unknown
- 2012-05-17 HR HRP20170754TT patent/HRP20170754T1/hr unknown
- 2012-05-17 ES ES17160386T patent/ES2758028T3/es active Active
- 2012-05-17 CA CA2834574A patent/CA2834574C/en active Active
- 2012-05-17 SM SM20190679T patent/SMT201900679T1/it unknown
- 2012-05-17 EP EP17160386.3A patent/EP3235812B1/en active Active
- 2012-05-17 PL PL12725197T patent/PL2709986T3/pl unknown
- 2012-05-17 RS RS20170601A patent/RS56096B1/sr unknown
- 2012-05-17 RS RS20191494A patent/RS59744B1/sr unknown
- 2012-05-17 DK DK12725197.3T patent/DK2709986T3/da active
- 2012-05-17 AU AU2012255711A patent/AU2012255711B2/en active Active
- 2012-05-17 LT LTEP12725197.3T patent/LT2709986T/lt unknown
- 2012-05-17 EP EP12725197.3A patent/EP2709986B1/en active Active
- 2012-05-17 WO PCT/US2012/038297 patent/WO2012158885A1/en not_active Ceased
- 2012-05-17 SI SI201231694T patent/SI3235812T1/sl unknown
- 2012-05-17 JP JP2014511524A patent/JP6063455B2/ja active Active
- 2012-05-17 PT PT171603863T patent/PT3235812T/pt unknown
- 2012-05-17 ES ES12725197.3T patent/ES2628465T3/es active Active
- 2012-05-17 ME MEP-2017-112A patent/ME02749B/me unknown
- 2012-05-17 PL PL17160386T patent/PL3235812T3/pl unknown
- 2012-05-17 EA EA201391615A patent/EA028378B1/ru unknown
- 2012-05-17 BR BR112013029240-7A patent/BR112013029240B1/pt active IP Right Grant
- 2012-05-17 HU HUE12725197A patent/HUE032771T2/en unknown
- 2012-05-17 PT PT127251973T patent/PT2709986T/pt unknown
- 2012-05-17 MX MX2013013450A patent/MX349159B/es active IP Right Grant
2016
- 2016-12-16 JP JP2016243941A patent/JP2017078082A/ja active Pending
2017
- 2017-06-02 CY CY20171100584T patent/CY1119090T1/el unknown
- 2017-07-27 AU AU2017208313A patent/AU2017208313A1/en not_active Abandoned
2019
- 2019-08-28 AU AU2019222862A patent/AU2019222862B2/en active Active
- 2019-11-25 HR HRP20192114TT patent/HRP20192114T1/hr unknown
- 2019-12-04 CY CY20191101275T patent/CY1122498T1/el unknown
2021
- 2021-02-15 AU AU2021200970A patent/AU2021200970B2/en active Active
- 2021-06-08 AU AU2021203786A patent/AU2021203786B2/en active Active

Also Published As

Publication number	Publication date
HUE032771T2 (en)	2017-10-30
PT2709986T (pt)	2017-06-26
PL2709986T3 (pl)	2017-09-29
AU2017208313A1 (en)	2017-08-17
SI2709986T1 (sl)	2017-07-31
AU2021203786B2 (en)	2023-03-16
DK2709986T3 (da)	2017-05-08
SI3235812T1 (sl)	2020-02-28
AU2012255711B2 (en)	2017-05-04
EP2709986B1 (en)	2017-03-22
CA2834574C (en)	2019-09-17
CY1119090T1 (el)	2018-01-10
EP3235812A1 (en)	2017-10-25
HK1244183A1 (en)	2018-08-03
AU2019222862B2 (en)	2021-03-11
WO2012158885A1 (en)	2012-11-22
CY1122498T1 (el)	2021-01-27
LT2709986T (lt)	2017-05-25
CA2834574A1 (en)	2012-11-22
ES2628465T3 (es)	2017-08-02
BR112013029240B1 (pt)	2023-05-16
PT3235812T (pt)	2019-12-09
HRP20192114T1 (hr)	2020-02-21
EP2709986A1 (en)	2014-03-26
JP2014515351A (ja)	2014-06-30
RS59744B1 (sr)	2020-02-28
AU2021203786A1 (en)	2021-07-08
RS56096B1 (sr)	2017-10-31
SMT201700302T1 (it)	2017-07-18
ME02749B (me)	2018-01-20
ES2758028T3 (es)	2020-05-04
PL3235812T3 (pl)	2020-04-30
EP3235812B1 (en)	2019-09-04
MX2013013450A (es)	2014-02-27
BR112013029240A2 (pt)	2017-01-31
EA028378B1 (ru)	2017-11-30
EA201391615A1 (ru)	2014-03-31
HRP20170754T1 (hr)	2017-07-28
JP6063455B2 (ja)	2017-01-18
ME03652B (me)	2020-07-20
SMT201900679T1 (it)	2020-01-14
AU2021200970B2 (en)	2022-07-14
JP2017078082A (ja)	2017-04-27
AU2019222862A1 (en)	2019-09-19
AU2021200970A1 (en)	2021-03-11
MX349159B (es)	2017-07-14

Publication	Publication Date	Title
SMT201900679T1 (it)	2020-01-14	Derivati deuterati di ivacaftor
DK3725778T4 (da)	2026-02-09	Formuleringer af enzalutamid
PL3450434T3 (pl)	2021-10-04	Deuterowane pochodne ruksolitynibu
DK2771364T3 (da)	2019-08-19	Fremstilling af heterodimere proteiner
EP2663266C0 (en)	2025-02-12	ENDOPROSTHESIS
CO6890099A2 (es)	2014-03-10	Nuevos derivados dihidroquinolina-2-ona
HUE047354T2 (hu)	2020-04-28	Ivacaftor deuterizált származékai
DK3156056T3 (da)	2024-02-26	Farmaceutiske sammensætninger der består af sorbitanestere
UY4115Q (es)	2012-07-31	Reloj
EP2673344A4 (en)	2016-08-17	STABLE BIO OIL
BR112014013850A2 (pt)	2017-06-13	conjunto de prateleiras
DK2733803T4 (da)	2019-06-24	Sektion af kabelbakke
IL231950B (en)	2018-02-28	Aryl-quinoline derivatives
DK3494993T3 (da)	2021-05-17	Ny anvendelse af maltotriosyl-transferase
EP2668926A4 (en)	2015-09-09	STENT IMPLANT
DK2800572T3 (da)	2017-11-20	Sammensætning af ellagitannin-rige ekstrakter
PT2790693T (pt)	2017-09-18	Administração de estatinas sublinguais
DK2692211T3 (da)	2019-11-04	Lysdæmperstyring af vinkellysfordeling
HUE036319T2 (hu)	2018-06-28	2-karboxamid-cikloamino-karbamidszármazékok szintézise
DK2571843T3 (da)	2018-01-29	Forbedret fremstilling af chalcon-derivater
DK2731572T3 (da)	2021-07-05	Forbedringer af indgivelsesanordninger
DK2888228T3 (da)	2019-07-15	Inhibitorer af CD40-TRAF6 interaktion
DK2838850T3 (da)	2021-12-13	Oprensning af titantetrachlorid
DK2407155T3 (da)	2013-04-02	Formuleringer af inecalcitol
DK2928896T3 (da)	2017-11-06	Fast form af dihydro-pyrido-oxazin-derivat